Pharmaceuticals Blog
FDA sends harsh warning letter concerning Avandia studies
April 9th, 2008 by Todd HagemanThe Food and Drug Administration recently sent a harsh warning letter to GlaxoSmithKline, the maker of the diabetes drug Avandia. According to Pharmalot, Glaxo failed to include nine post-marketing studies in a mandatory report to the FDA. A Glaxo spokesperson is claiming this to be an “inadvertent omission.”
A few months ago, the FDA ordered Glaxo to put stronger “black box” warnings on the packaging.
If you or someone you know has been hurt as a result of taking a dangerous medication, contact Todd Hageman toll free at 1-877-767-3108.
